Clinical trialPhase 1Completed
Study of a New Technique for Imaging Pancreatic Cancer
89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging in Pancreatic Cancer or Other CA19-9 Positive Malignancies
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 10 May 2021
- Expected end
- 27 January 2025
- Enrollment
- 4 participants
- Sites
- 7
- Primary outcomes
- Number of subjects with treatment-related adverse events as assessed; Biodistribution of MVT-2163
- Sponsor
- Other
- Results posted
- No
- Last update
- 30 January 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to see how well the experimental imaging agent 89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done with this imaging agent produce better images of cancer.